+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Cancer Nuclear Medicine Diagnostics Market by Radiopharmaceutical, Modality, End User, Indication - Global Forecast to 2030- Product Image
Prostate Cancer Nuclear Medicine Diagnostics Market by Radiopharmaceutical, Modality, End User, Indication - Global Forecast to 2030- Product Image
Sale

Prostate Cancer Nuclear Medicine Diagnostics Market by Radiopharmaceutical, Modality, End User, Indication - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5639599
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Prostate Cancer Nuclear Medicine Diagnostics Market grew from USD 1.15 billion in 2024 to USD 1.31 billion in 2025. It is expected to continue growing at a CAGR of 12.86%, reaching USD 2.39 billion by 2030.

Unveiling Advances in Prostate Cancer Nuclear Medicine Diagnostics

Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, and nuclear medicine diagnostics have become integral to early detection, staging, and treatment monitoring. This executive summary synthesizes the current state of nuclear medicine modalities, radiopharmaceutical innovations, and clinical practices that are transforming diagnostic pathways. By examining key drivers, emerging technologies, and regulatory influences, stakeholders can navigate a landscape defined by precision imaging and targeted molecular tracers.

The rapid evolution of prostate-specific membrane antigen (PSMA) imaging agents, advanced digital detectors, and hybrid systems underscores a commitment to enhancing sensitivity and specificity. Clinical adoption continues to rise as healthcare providers recognize the value of accurate localization and quantification of disease. Meanwhile, ongoing collaborations between research institutions, industry players, and regulatory bodies are shaping protocols and reimbursement frameworks. This summary provides a foundation for understanding the forces reshaping prostate cancer diagnostics and highlights strategic considerations for decision-makers aiming to drive clinical impact and commercial success.

Shifts in the Diagnostic Landscape Driven by Innovation

The diagnostic landscape for prostate cancer is undergoing transformative shifts driven by technological breakthroughs and refined clinical strategies. The introduction of PSMA-targeted radiotracers has redefined sensitivity benchmarks, enabling detection of micro-metastatic lesions that were previously elusive. Parallel advancements in digital PET systems and time-of-flight imaging have accelerated scan times, improved resolution, and enhanced image quantification, supporting more precise treatment planning.

Moreover, integration of artificial intelligence algorithms for image reconstruction and lesion characterization is gaining momentum. These tools streamline workflows, reduce interobserver variability, and offer predictive insights based on radiomic features. In tandem with emerging agents such as fluorinated PSMA compounds and copper-based tracers, this wave of innovation is facilitating personalized diagnostics. The shift towards theranostic approaches, which pair diagnostic scans with targeted radionuclide therapies, further exemplifies the convergence of imaging and treatment, promising comprehensive management of recurrent and advanced disease stages.

Evaluating the Effects of 2025 US Tariffs on Nuclear Medicine

In 2025, the United States implemented new tariffs that directly influence the importation of key radiopharmaceutical precursors and imaging equipment. These changes have led to recalibrated supply chains, with some providers experiencing increased reagent costs and extended lead times. To navigate this environment, organizations are exploring strategic stockpiling, diversifying supplier networks, and engaging domestic manufacturers to mitigate exposure to cross-border tariff fluctuations.

The impact on diagnostic centers is multifaceted: higher operational expenses may translate into adjustments in scanning volumes or procedural reimbursements. At the same time, stakeholders are negotiating with regulators to secure exemptions for critical diagnostic agents and advocating for streamlined customs processes. Collaborative efforts between industry associations and government agencies are underway to foster resilience in radiopharmaceutical supply and maintain uninterrupted patient access to advanced imaging services.

Comprehensive Segmentation Insights Powering Diagnostic Precision

Market segmentation illuminates the diverse radiopharmaceutical agents driving prostate cancer diagnosis. Eleven carbon-labeled choline tracers pioneered molecular imaging, but second-generation compounds such as fluorinated DCFPyL and fluciclovine have achieved broader clinical integration. Gallium-68 PSMA has established itself as a standard for high-contrast lesion detection, while emerging agents like fluorinated PSMA-1007 and copper-64 PSMA are under investigation for improved pharmacokinetics and imaging resolution.

Diagnostic modalities shape the technical landscape, with hybrid PET/CT remaining the gold standard. Conventional PET systems are evolving into digital platforms with time-of-flight capabilities, offering faster scans and enhanced signal-to-noise ratios. Similarly, single-photon emission computed tomography has progressed toward SPECT/CT hybrids, integrating conventional gamma camera technology with computed tomography to refine anatomical localization.

End users encompass academic research institutes that drive methodological innovation, diagnostic centers focused on outpatient imaging workflows, and hospitals that integrate nuclear medicine into multidisciplinary oncology care. Each setting prioritizes different operational metrics, from throughput and cost management to integration with therapeutic services.

Clinical indications are equally nuanced, extending beyond initial staging to biochemical recurrence detection and longitudinal treatment monitoring. Early biochemical relapse cases benefit from high-sensitivity tracers that inform salvage radiotherapy decisions, while ongoing assessments of metastatic burden guide systemic therapy adjustments.

Regional Dynamics Shaping Market Growth Trajectories

Regional analysis reveals distinct adoption patterns across the Americas, Europe, Middle East and Africa, and Asia-Pacific. In the Americas, established reimbursement pathways and a strong payer landscape support rapid uptake of novel tracers and advanced PET instrumentation. Leading academic centers spearhead clinical trials, while community hospitals expand service portfolios to include PSMA imaging for recurrent disease.

The Europe, Middle East and Africa region demonstrates a heterogeneous regulatory environment. Western Europe’s centralized approval processes enable faster market entry for new radiopharmaceuticals, whereas certain Middle Eastern markets leverage public-private partnerships to accelerate infrastructure development. Africa remains an emerging frontier, with capacity-building initiatives focused on workforce training and equipment acquisition.

Asia-Pacific showcases dynamic growth driven by large patient populations and escalating healthcare investments. Countries such as Japan and South Korea are early adopters of cutting-edge imaging modalities, integrating digital PET and next-generation tracers into national cancer control programs. In contrast, South and Southeast Asia are advancing through targeted pilot projects and collaborations designed to establish regional centers of excellence.

Spotlight on Leading Innovators in Nuclear Medicine Diagnostics

Key players in the nuclear medicine diagnostics arena span radiopharmaceutical manufacturers, imaging device vendors, and dedicated service providers. Leading pharmaceutical innovators are expanding their pipelines with next-generation PSMA ligands and partnering with academic institutions to validate clinical utility across diverse patient cohorts. Concurrently, medical imaging firms are enhancing digital detector technologies and workflow software to optimize scanner utilization and data analytics.

Contract research organizations and specialty radiopharmacy networks play a pivotal role in distributing radiolabeled tracers while ensuring compliance with stringent quality standards. Strategic alliances between equipment manufacturers and tracer developers facilitate co-development programs, integrating hardware and radiopharmaceutical solutions into cohesive diagnostic packages. These collaborations aim to shorten time to market and create seamless user experiences for clinicians and technologists alike.

As competitive intensity escalates, some enterprises are forging joint ventures to address regional supply chain constraints, particularly in locales with emerging regulatory frameworks. Investment in manufacturing scalability and cold chain logistics underpins readiness for next-generation agents, positioning these companies at the forefront of clinical adoption.

Strategic Recommendations to Elevate Diagnostic Leadership

Industry leaders must prioritize strategic alliances with domestic radiopharmacy networks to bolster supply resilience and mitigate tariff exposure. Investing in advanced PET/CT and SPECT/CT technologies, particularly digital and time-of-flight systems, will enhance diagnostic accuracy and throughput while addressing growing demand for high-sensitivity imaging in biochemical recurrence scenarios.

Engagement with regulatory agencies is essential to secure early access designations and navigate evolving tariff regulations. Organizations should allocate resources to health economics research and real-world evidence generation, supporting favorable reimbursement policies across key markets. Embracing multidisciplinary collaboration, cross-functional teams can streamline integration of diagnostic data into personalized treatment pathways, reinforcing the theranostic paradigm.

Furthermore, educational initiatives targeting oncologists, urologists, and nuclear medicine specialists will drive informed adoption of novel tracers. By articulating clinical value through peer-reviewed publications and congress presentations, stakeholders can influence guideline committees and cement the role of advanced diagnostics in standard care protocols.

Underpinning the Study with Rigorous Research Methodology

This market analysis relied on a rigorous combination of primary and secondary research methodologies. Secondary data sources included peer-reviewed journals, regulatory filings, clinical trial registries, and industry white papers. These insights were cross-referenced with financial reports and strategic announcements from leading corporations to ensure a holistic understanding of market dynamics.

Primary research involved in-depth interviews with key opinion leaders, including nuclear medicine physicians, radiochemists, healthcare administrators, and procurement specialists. Their perspectives validated technological trends, identified unmet clinical needs, and assessed the operational impact of regulatory changes. A structured questionnaire framework guided these discussions, ensuring consistency across stakeholder groups.

Data were triangulated through quantitative and qualitative analyses, with emerging themes subjected to expert peer review. This process reinforced the accuracy of segmentation insights, regional dynamics, and competitive benchmarks. Ethical considerations and confidentiality protocols were strictly observed throughout the research lifecycle.

Synthesizing Insights to Propel Diagnostic Advancements

Prostate cancer nuclear medicine diagnostics stand at the threshold of unprecedented precision and clinical utility. The convergence of advanced radiopharmaceuticals, cutting-edge imaging platforms, and data-driven workflows is redefining patient pathways from initial staging to treatment monitoring. Segmentation analysis underscores the importance of selecting the optimal tracer modality, end-user environment, and clinical indication to maximize diagnostic yield.

Regional insights highlight both mature markets, where regulatory and reimbursement structures facilitate swift adoption, and emerging regions poised for rapid infrastructure development. Competitive landscapes emphasize the critical role of strategic partnerships, manufacturing scalability, and integrated solution offerings. By aligning innovation with stakeholder needs, industry participants can accelerate the transition toward personalized, theranostic care models.

Collectively, these insights furnish a roadmap for decision-makers to navigate regulatory complexities, optimize technology investments, and shape clinical guidelines. The strategic recommendations presented herein serve as actionable levers for sustaining growth and driving meaningful improvements in patient outcomes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Radiopharmaceutical
    • 11C Choline
    • 18F DcfpyL
    • 18F Fluciclovine
    • 68Ga Psma
    • Emerging Agents
      • 18F Psma 1007
      • 64Cu Psma
  • Modality
    • Pet
      • Digital Pet
      • Time Of Flight Pet
    • Spect
      • Conventional Spect
      • Spect Ct
  • End User
    • Academic Research Institute
    • Diagnostic Center
    • Hospital
  • Indication
    • Biochemical Recurrence Detection
    • Initial Staging
    • Treatment Monitoring
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • GE HealthCare Technologies Inc.
  • Siemens Healthineers AG
  • Koninklijke Philips N.V.
  • Cardinal Health, Inc.
  • Bayer AG
  • Lantheus Holdings, Inc.
  • Bracco Imaging S.p.A.
  • Telix Pharmaceuticals Limited
  • Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Isotope Technologies Munich SE

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Prostate Cancer Nuclear Medicine Diagnostics Market, by Radiopharmaceutical
8.1. Introduction
8.2. 11C Choline
8.3. 18F DcfpyL
8.4. 18F Fluciclovine
8.5. 68Ga Psma
8.6. Emerging Agents
8.6.1. 18F Psma 1007
8.6.2. 64Cu Psma
9. Prostate Cancer Nuclear Medicine Diagnostics Market, by Modality
9.1. Introduction
9.2. Pet
9.2.1. Digital Pet
9.2.2. Time of Flight Pet
9.3. Spect
9.3.1. Conventional Spect
9.3.2. Spect Ct
10. Prostate Cancer Nuclear Medicine Diagnostics Market, by End User
10.1. Introduction
10.2. Academic Research Institute
10.3. Diagnostic Center
10.4. Hospital
11. Prostate Cancer Nuclear Medicine Diagnostics Market, by Indication
11.1. Introduction
11.2. Biochemical Recurrence Detection
11.3. Initial Staging
11.4. Treatment Monitoring
12. Americas Prostate Cancer Nuclear Medicine Diagnostics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. GE HealthCare Technologies Inc.
15.3.2. Siemens Healthineers AG
15.3.3. Koninklijke Philips N.V.
15.3.4. Cardinal Health, Inc.
15.3.5. Bayer AG
15.3.6. Lantheus Holdings, Inc.
15.3.7. Bracco Imaging S.p.A.
15.3.8. Telix Pharmaceuticals Limited
15.3.9. Eckert & Ziegler Strahlen- und Medizintechnik AG
15.3.10. Isotope Technologies Munich SE
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 49. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 50. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 51. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 52. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 53. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 56. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 57. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 58. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 59. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 60. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 92. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 93. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 94. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 95. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 96. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 99. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 100. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 101. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 102. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 103. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 113. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 114. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 115. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 116. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 117. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 120. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 121. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 122. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 123. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 124. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 148. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 149. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 150. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 151. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 152. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 162. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 163. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 164. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 165. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 166. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 169. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 170. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 171. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 172. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 173. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 190. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 191. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 192. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 193. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 194. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 197. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 198. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 199. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 200. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 201. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 211. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 212. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 213. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 214. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 215. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 217. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 218. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 219. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 220. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 221. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 222. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 240. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 241. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 242. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 243. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 244. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 247. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 248. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 249. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 250. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 251. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 253. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 254. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 255. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 256. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 257. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 258. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA

Companies Mentioned

The companies profiled in this Prostate Cancer Nuclear Medicine Diagnostics market report include:
  • GE HealthCare Technologies Inc.
  • Siemens Healthineers AG
  • Koninklijke Philips N.V.
  • Cardinal Health, Inc.
  • Bayer AG
  • Lantheus Holdings, Inc.
  • Bracco Imaging S.p.A.
  • Telix Pharmaceuticals Limited
  • Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Isotope Technologies Munich SE

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.31 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.39 Billion
Compound Annual Growth Rate12.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2025 - Product Image

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Nuclear Medicine/Radiopharmaceuticals - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Nuclear Medicine/Radiopharmaceuticals - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Nuclear Medicine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Nuclear Medicine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters)), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters)), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 170 Pages
  • Global
From
Nuclear Medicine Radioisotopes Market Report 2025 - Product Image

Nuclear Medicine Radioisotopes Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Prostate Cancer Nuclear Medicine Diagnostics Market

Prostate cancer nuclear medicine diagnostics is a segment within the broader field of medical diagnostics focused on using nuclear medicine techniques to detect and evaluate prostate cancer. Nuclear medicine is a medical specialty that employs small amounts of radioactive materials, known as radiopharmaceuticals, to diagnose and sometimes treat diseases. In prostate cancer diagnosis, these radiopharmaceuticals are designed to target specific molecules associated with the presence of cancer cells, such as the prostate-specific membrane antigen (PSMA). Imaging technologies like Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) are utilized in conjunction with these radiotracers to visualize the distribution of the radioactive material within the prostate gland and surrounding tissues. This enables physicians to detect the presence and extent of prostate cancer, thereby guiding treatment decisions and prognostication. Key players in the prostate cancer nuclear medicine diagnostics market include companies that specialize in the production of radiopharmaceuticals, as well as those that manufacture the imaging equipment used in the diagnostic process. Some prominent companies in this market are Advanced Accelerator Applications (a subsidiary of Novartis), Blue Earth Diagnostics (a Bracco company), Progenics Pharmaceuticals (part of Lantheus Medical Imaging), IsoRay Medical, and Bayer AG. These companies engage in research and development to improve the specificity and sensitivity of nuclear diagnostic agents for prostate cancer and strive to create advanced imaging systems for more precise disease characterization. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.